Lapatinib-d7

Lapatinib-d7 (GW572016-d7) is deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1].

Product Specifications

CAS Number

[1009307-23-6]

Product Name Alternative

GW572016-d7; GW2016-d7

UNSPSC

12352005

Target

Autophagy; EGFR; Ferroptosis; Isotope-Labeled Compounds

Related Pathways

Apoptosis; Autophagy; JAK/STAT Signaling; Others; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

[2H]C([2H])([2H])S(C([2H])([2H])C([2H])([2H])NCC1=CC=C(O1)C2=CC(C(NC3=CC(Cl)=C(C=C3)OCC4=CC(F)=CC=C4)=NC=N5)=C5C=C2)(=O)=O

Molecular Formula

C29H19D7ClFN4O4S

Molecular Weight

588.10

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Rusnak DW, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 2001 Dec;1 (2) :85-94